Aneuploidies account for approximately 50% of the causes of early fetal death during pregnancy, leading to what is known as miscarriage — the most common pregnancy outcome, affecting approximately 1 in 7 confirmed pregnancies. This chromosome abnormality causes imbalances in gene dosage that disrupt normal gene expression, which is critical for embryonic development and viability. While the consequences of aneuploidies on preimplantation embryos has been widely studied, the transcriptional consequences of aneuploidies in clinical pregnancies (ranging from 6 to 23 gestational weeks) has not been explored to date. This study will utilize publicly available RNA sequencing data from placental villi from pregnancies undergoing non-medical elective termination. We aim to identify regulatory signatures of mid-pregnancy fetal development associated with chromosomal aneuploidies and whether these signatures are altered across different developmental stages. Understanding these differences in gene expression could provide important insights into the mechanisms underlying fetal loss and propel the understanding of the fundamental dynamics of early development.